Strategies and developments of immunotherapies in osteosarcoma

Oncology Letters
Jia WanXiangsheng Zhang

Abstract

Osteosarcoma (OS) is a frequently observed primary malignant tumor. Current therapy for osteosarcoma consists of comprehensive treatment. The long-term survival rate of patients exhibiting nonmetastatic OS varies between 65-70%. However, a number of OS cases have been observed to be resistant to currently used therapies, leading to disease recurrence and lung metastases, which are the primary reasons leading to patient mortality. In the present review, a number of pieces of evidence provide support for the potential uses of immunotherapy, including immunomodulation and vaccine therapy, for the eradication of tumors via upregulation of the immune response. Adoptive T-cell therapy and oncolytic virotherapy have been used to treat OS and resulted in objective responses. Immunologic checkpoint blockade and targeted therapy are also potentially promising therapeutic tools. Immunotherapy demonstrates significant promise with regard to improving the outcomes for patients exhibiting OS.

References

Apr 15, 1977·International Journal of Cancer. Journal International Du Cancer·H Strander, S Einhorn
Jul 1, 1990·Immunology Today·H G Ljunggren, K Kärre
Jun 21, 1989·Journal of the National Cancer Institute·E G MacEwenP E Howard
Jan 1, 1995·Acta Oncologica·H StranderV Söderlund
Apr 1, 1995·Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy·E S KleinermanN Jaffe
Apr 1, 1995·American Journal of Clinical Oncology·E S KleinermanN Jaffe
Apr 1, 1997·Proceedings of the National Academy of Sciences of the United States of America·R P TomkoL Philipson
Apr 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J W Shay, S Bacchetti
Jan 12, 2001·Clinical Orthopaedics and Related Research·C D MorrisJ H Healey
Sep 10, 2002·Journal of Pediatric Hematology/oncology·Neeti S BharatanTimothy P Cripe
Sep 14, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ronald BukowskiCraig L Tendler
Oct 2, 2002·Current Oncology Reports·Daniel J Lindner
Jan 22, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Adhiambo M WitloxWinald R Gerritsen
Aug 26, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Roland L ChuErwin G Van Meir
Mar 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul A MeyersHolcombe Grier
Apr 26, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·W SchwingerC Urban
Sep 2, 2006·Science·Richard A MorganSteven A Rosenberg
Feb 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul A MeyersUNKNOWN Children's Oncology Group
Mar 21, 2008·Nature Reviews. Cancer·Steven A RosenbergMark E Dudley
Jun 14, 2008·Expert Opinion on Investigational Drugs·Kaitlyn J KellyYuman Fong
Aug 5, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Crystal L MackallLee J Helman
Sep 11, 2008·Reviews on Recent Clinical Trials·Akio Sakamoto, Yukihide Iwamoto
Jun 18, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Nabil AhmedStephen Gottschalk
Jul 25, 2009·Nature Reviews. Immunology·David H Raulet, Nadia Guerra
Nov 11, 2009·Pediatric Blood & Cancer·Jeremy WhelanMark Bernstein
Feb 25, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Richard A MorganSteven A Rosenberg
Mar 10, 2010·Cancer Treatment and Research·David M Loeb
Jun 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie R BrahmerSuzanne L Topalian

❮ Previous
Next ❯

Citations

Sep 30, 2016·Frontiers in Immunology·Zhan WangZhaoming Ye
Sep 20, 2017·International Journal of Molecular Sciences·Denis GümbelMatthias B Stope
Dec 19, 2016·F1000Research·Stefan S BielackLeo Kager
Sep 22, 2016·Future Oncology·Leo KagerStefan Bielack
Nov 2, 2019·Cancer Biotherapy & Radiopharmaceuticals·Jicheng WangZhi Yi
Dec 6, 2017·Molecular Medicine Reports·Quanming WuMingpeng Li
Dec 10, 2016·Rheumatology and Therapy·Brock A LindseyEugenie S Kleinerman
Jan 19, 2018·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Qingbing MengMinqian Zheng
Oct 27, 2017·Acta Veterinaria Scandinavica·Siobhan SimpsonCatrin Sian Rutland
May 14, 2016·Medical Science Monitor : International Medical Journal of Experimental and Clinical Research·Zhi ChenQinghao Guo
Dec 24, 2018·Cancer Cell International·Gan GaoXun-Yan Ouyang
Feb 14, 2018·International Journal of Molecular Medicine·Qingbing MengMinqian Zheng
Jan 21, 2021·International Journal of Molecular Sciences·Isabel FernandesLuís Costa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.